Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure.
Wisløff
Finn
F
Hematological Research Laboratory, Department of Hematology, Ullevål University Hospital, Kirkeveien 166, 0407 Oslo, Norway. f.g.b.wisloff@medisin.uio.no
Crowther
Mark
M
D000026:Abortion, Habitual / Q000517:prevention & control*; D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000196:embryology; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine / Q000379:methods*; D005260:Female; D005313:Fetal Death / Q000517:prevention & control*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010818:Practice Patterns, Physicians'; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D016756:Immunoglobulins, Intravenous; D006493:Heparin; D001241:Aspirin; D011241:Prednisone